top of page
A patient-friendly breast cancer blood test-5.png

Welcome to BCAL

BCAL is commercialising a next-generation, patient-friendly blood test to enable more effective diagnosis of breast cancer alongside other screening methods


Are you interested in investing in the future of BCAL Diagnostics (ASX: BDX). 


Would you like to learn more about our scientific advances?


Would you like to register your interest in participating in our clinical trials?

A Leading Biotechnology Company

BCAL Diagnostics Limited is an Australian biotechnology company committed to improved health outcomes for women. Over the past decade, BCAL has developed a non-invasive blood screening technology that is initially intended to be used alongside breast cancer screening methods, with results to date demonstrating 90% sensitivity and 85.5% specificity. The technology will initially complement current imaging technologies, such as the mammogram, while BCAL further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location.


With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with Precion Inc. to optimise protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions, commercialisation and market entry points.


Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX).

About BCAL Diagnostics


Get Involved

BCAL Diagnostics is developing a blood screening tool that is intended to be used alongside breast cancer screening methods 


If you'd like to participate in our clinical trials, please register via the link below.

Subscribe for our monthly updates

Thanks for subscribing

bottom of page